· Center for Drug and Alcohol Programs,· Medical University of South Carolina
Charleston, South Carolina, 29425, United States
NCT Number: NCT00366626
The purpose of this study is to determine whether naltrexone (an opiate blocking agent approved for the treatment of alcohol dependence) is more effective in the reduction of alcohol craving and drinking compared to placebo in individuals with particular genetic predisposition.
Looking for future studies?
Notify Me21 year–65 year
All sexes
Interventional
Phase 4
Charleston, South Carolina, 29425, United States
About 300 non-treatment seeking alcoholics will be recruited through advertisement and paid for their participation. They will be assessed, subtyped for mu-opiate receptor and catechol-O-methyltransferase (COMT) allelic variants and 88 individuals (44 with the more common AA gene and 44 with either an AG or GG gene) will be randomly assigned to take either naltrexone (50 mg/day) or a matching placebo for 7 days. Since the val and met alleles of the catechol-O-methyltransferase (COMT) gene are each present in about 50% of the population they will be equally distributed by urn randomization to all opiate allele and treatment groups. After 5 days of natural drinking and one day of abstinence, subjects will undergo an alcohol cue-induced brain activity scan using well-established fMRI techniques on Day 6 of study drug. The following day all subjects will receive a standard dose (gender and weight corrected) of alcohol and be evaluated for alcohol reactivity (stimulation, sedation, intoxication, craving) over 40 minutes. They then will be allowed to consume up to 8 mini-drinks over a 2-hour period. Afterwards all subjects will receive educational/motivational counseling regarding their alcohol use and its effects. Referral for treatment will be offered.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion for fMRI imaging sub-study (see methodology section for rationale):
Exclusion criteria
Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
Other names: ReVia
Placebo for 7 days matched to Naltrexone
Time frame: treatment days 1 - 5
Time frame: On day 7 of treatment during limited access alcohol consuption in the bar/laboratory
Subjects were allowed to drink up to 8 alcohol drinks during 2 hours observation period being in bar/laboratory settings vs to get $2 per each not consumed drink.
Medical University of South Carolina
Other
Alcohol Research Center Grant. Component #1: Naltrexone Effects on Alcohol Reactivity and Consumption, Evaluating the Genetic Variability of Naltrexone Response
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04007042
Alcohol Dependence, Alcohol-Related Disorders
Nîmes, Gard, France
View Trial DetailsNCT04154111
Alcohol Abuse, Alcohol Dependence
Winston-Salem, North Carolina, United States
View Trial DetailsNCT03952429
Alcohol Abuse, Alcohol Dependence
Lindow, Brandenburg, Germany
View Trial DetailsNCT02438969
Alcohol Dependence, Alcohol-Related Disorders
Bethesda, Maryland, United States
View Trial Details